Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (May 2018)
12 slides from Senseonics's investor presentation, May 30, 2018
Slide 1: Forward-Looking Statements
Forward-Looking Statements In some cases, you can identify forward-looking statements by the words “expect,” “intend,” “target,” “plan,” “estimate,” “predict,” “opportunity,” and “continue,” or the negative of these terms, or other comparable terminology intended to identify statements about the fut
Slide 2: Develop and commercialize transformative glucose monitoring products
confidently live life with ease develop and commercialize transformative glucose monitoring products. 3
Slide 3: Diabetes Is a Lifetime Disease with Many Stages
Diabetes Is lifetime Disease with Many Stages Monitor Glucose to Ensure Within Range Syringe / Pens Pumps Increasing Severity CGM Application Today Type 1 Therapy Regimen Oral Therapies Diet and Exercise GLP-1s Basal Insulin Rapid Acting Insulin Intensively Managed Type 2 4
Slide 4: Monitoring and Managing Is Key To Disease Management
Monitoring and Managing Is Key To Disease Management How does glucose monitoring do this? By showing patterns and trends, with proper management time in hypo- and hyperglycemia ranges can be reduced 70% of the time patients are outside the healthy range Benefits and Limita'ons of Self-Monitoring of
Slide 5: CGM Gives You Better Insight
CGM Gives You Better Insight Glucose Concentration (mg/dL) Target Range HYPOGLYCEMIA HYPERGLYCEMIA Eversense Glucose Readings SMBG SMBG SMBG SMBG 8AM 12PM 4PM 8PM 12PM 4AM Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limi
Slide 6: Diabetes Technology Segments
Diabetes Technology Segments 2015 2020 Est. 2015 2020 Est. 2015 2020 Est. CGM fastest growing segment Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United States. ~35 –
Slide 7: Continuous Glucose Monitoring
Mid- 2000’s Continuous Glucose Monitoring MEDTRONIC DEXCOM ABBOTT TODAY Late 90’s MEDTRONIC DEXCOM ABBOTT SENSEONICS Eversense CGM System is CE marked and approved for sale in Europe. Eversense CGM System is an Investigational Device and is limited by Federal Law to investigational use in the United
Slide 8: U.S. Market Potential – $18B
U.S. Market Potential – $18B 9 have an unmet need And CGM can contribute across the spectrum 6.9 M Insulin Taking Patients 23M Patients diagnosed with Diabetes 3.9M Insulin only (57%) 3M Insulin and oral (43%) 600K Pump $2.3B 250K CGM $750M Opportunity continues to expand National Diabetes Statistic
Slide 9: The first & only fully implantable CGM sensor
The first & only fully implantable CGM sensor for confident long-term glucose monitoring Highest Accuracy Longest Sensor Life Best Convenience 10 Eversense Advantage
Slide 10: The Eversense future 2020 and beyond
The Eversense future 2020 and beyond 12 On-Demand: Type 2 FGM Long-term wear with no transmitter Type 1 : Gemini FGM +CGM Flash when desired, CGM for peace of mind 365 Day Sensor Life 1x/week calibration 365 Day Sensor Life 1x/week calibration
Slide 11: An Implantable CGM: What does it mean for patients?
An Implantable CGM What does it mean for patients? Less Hassle Fewer Decisions More Flexibility, Freedom 13 A new Standard for CGM Enabling enhanced adherence and actionable information
Slide 12: An Implantable CGM: What does it mean for patients?
An Implantable What does it mean for patients? Anew Standard Enabling enhanced adherence for CGM and actionable information Senseonics. 13
Senseonics Holdings — Investor Presentation (May 2018) on 6ix